New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
07:51 EDTFOLDAmicus Theraputics sees FY13 cash spend $52M-$58M
Cash, cash equivalents, and marketable securities totaled $99.1M at December 31, 2012 compared to $55.7M at December 31, 2011. Amicus expects FY13 net cash spend between $52M-$58M. The current cash position and anticipated Fabry program reimbursements from GSK are projected to fund operations into the second half of 2014.
News For FOLD From The Last 14 Days
Check below for free stories on FOLD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
11:08 EDTFOLDHigh option volume stocks
Subscribe for More Information
11:06 EDTFOLDSummer Street chief scientific officer holds an analyst/industry conference call
Chief Scientific Officer Classen discusses Amicus Therapeutics' Migalastat for Fabry's disease on an Analyst/Industry conference call to be held on July 23 at 2 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use